CredoScientia - Bibliothèque

Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review.

Malignant mesothelioma (MM) is a tumor originating from the pleura, peritoneum, or pericardial cavity. It is divided into diffuse and localized malignant mesothelioma, with four subtypes in diffuse M…

Thérapies de Conversion

Deng, M., Zhang, X., Xu, C., Luo, R., Chen, L., Zhou, Y., & Hou, Y. (2023). Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review.. Pathol Oncol Res, 29, 1611577. https://doi.org/10.3389/pore.2023.1611577

01/01/2023 Lire →

Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?

BACKGROUND: This study aimed to determine whether salvage hepatectomy offers prognostic advantages for unresectable hepatocellular carcinoma (uHCC) patients with clinical complete response (cCR) after…

Thérapies de Conversion

Wu, J. Y., Wu, J. Y., Liu, D. Y., Li, H., Zhuang, S. W., Li, B., Zhou, J. Y., Huang, J. Y., Zhang, Z. B., Li, S. Q., Yan, M. L., & Wang, Y. D. (2023). Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?. J Hepatocell Carcinoma, 10, 2161-2171. https://doi.org/10.2147/JHC.S442341

01/01/2023 Lire →

Hormonal changes resulting from transgender conversion therapy may represent a gap in the biological effects of radiation understanding.

Thérapies de Conversion

Andrade, E. R. (2023). Hormonal changes resulting from transgender conversion therapy may represent a gap in the biological effects of radiation understanding.. Int J Radiat Biol, 99(11), 1800-1801. https://doi.org/10.1080/09553002.2023.2211147

01/01/2023 Lire →

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.

As stage IIIC non-small cell lung cancer (NSCLC) is not recommended for surgical resection, the survival and prognosis for stage IIIC NSCLC remain poor. More powerful and individualized therapies are …

Thérapies de Conversion

Fu, Y., Duan, W., Xu, R., & Chen, J. (2023). Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.. Front Immunol, 14, 1268153. https://doi.org/10.3389/fimmu.2023.1268153

01/01/2023 Lire →

Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.

BACKGROUND: Currently, gastric cancer with positive lavage cytology without gross peritoneal dissemination (GC-CY1) is a special type of metastatic form with poor prognosis. Consensus guidelines on tr…

Thérapies de Conversion

Lv, J., Wu, J., Wu, H., Ding, P., Guo, H., Yang, P., Tian, Y., Liu, Y., & Zhao, Q. (2023). Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.. Front Oncol, 13, 1201928. https://doi.org/10.3389/fonc.2023.1201928

01/01/2023 Lire →

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

OBJECTIVE: This study was aimed to evaluate the efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of unresectable hepato…

Thérapies de Conversion

Li, J., Kong, M., Yu, G., Wang, S., Shi, Z., Han, H., Lin, Y., Shi, J., & Song, J. (2023). Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.. Front Immunol, 14, 1188308. https://doi.org/10.3389/fimmu.2023.1188308

01/01/2023 Lire →

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.

PURPOSE: The purpose of this study was to investigate the triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy as a conversion therapy for initially unresectable h…

Thérapies de Conversion

Gan, L., Lang, M., Tian, X., Ren, S., Li, G., Liu, Y., Han, R., Zhu, K., Li, H., Wu, Q., Cui, Y., Zhang, W., Fang, F., Li, Q., & Song, T. (2023). A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 10, 673-686. https://doi.org/10.2147/JHC.S404675

01/01/2023 Lire →

Evolving jurisprudence on conversion therapy: Reconsidering ethics in mental health systems.

Since the Delhi High Court judgement (2009), reading down IPC 377 that criminalised homosexuality, the Indian judiciary has been at the forefront of invoking constitutional morality to uphold LGBTQIA+…

Thérapies de Conversion

Kottai, S. R., & Ramprakash, R. (2023). Evolving jurisprudence on conversion therapy: Reconsidering ethics in mental health systems.. Indian J Med Ethics, VIII(4), 296-302. https://doi.org/10.20529/IJME.2023.024

01/01/2023 Lire →